Published in J Am Coll Surg on April 01, 2005
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant (2011) 1.20
Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant (2011) 1.10
CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci (2005) 1.06
Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant (2007) 1.04
Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy (2011) 1.02
Composite tissue allotransplantation immunology. Arch Plast Surg (2013) 0.97
Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97
The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93
Steroid elimination is coming of age. Pediatr Nephrol (2005) 0.84
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation (2006) 0.82
Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant (2007) 0.81
The mystique of organ transplantation. J Am Coll Surg (2005) 0.78
Kidney after nonrenal transplantation-the impact of alemtuzumab induction. Transplantation (2009) 0.78
Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity. Am J Transplant (2013) 0.78
Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation. Clin Exp Nephrol (2012) 0.77
BIOMARKERS OF OPERATIONAL TOLERANCE IN SOLID ORGAN TRANSPLANTATION. Expert Opin Med Diagn (2012) 0.77
Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int (2012) 0.77
Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals. Transplantation (2017) 0.76
Induction of tolerance in clinical kidney transplantation. Clin Transplant (2010) 0.76
The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug Des Devel Ther (2009) 0.76
A Double-Blind, Double-Dummy, Flexible-Design Randomized Multicenter Trial: Early Safety of Single- Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation. Am J Transplant (2016) 0.75
Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus model. Chin Med J (Engl) (2015) 0.75
Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction. Transplantation (2008) 0.75
Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients. Transplant Proc (2007) 0.75
Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center. Int J Organ Transplant Med (2015) 0.75
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl (1968) 3.41
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation (2004) 1.82
Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation (2001) 1.68
Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation (1995) 1.53
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation (1994) 1.39
Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol (1999) 1.37
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg (2005) 1.10
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation (1989) 1.03
Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation (1991) 1.00
Specificity of monoclonal antibody Campath-1. Bone Marrow Transplant (1988) 0.95
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated donor bone marrow transplantation. Transplantation (1994) 0.87
Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation (1997) 0.85
Optimising a limiting dilution culture system for quantitating frequencies of alloreactive cytotoxic T lymphocyte precursors. Cell Immunol (1991) 0.84
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07
Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med (2006) 2.77
Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med (2005) 2.67
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl (2002) 2.38
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 2.38
VENO-VENOUS BYPASS WITHOUT SYSTEMIC ANTICOAGULATION IN CANINE AND HUMAN LIVER TRANSPLANTATION. Surg Forum (1983) 2.30
Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion (2006) 2.26
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
THE USE OF COMBINED PRESERVATION TECHNIQUES FOR EXTENDED STORAGE OF ORTHOTOPIC LIVER HOMOGRAFTS. Surg Gynecol Obstet (1968) 2.20
The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl (2008) 2.11
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07
Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl (2006) 2.02
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology (2004) 1.92
Depression, stress, and social support as predictors of high-risk sexual behaviors and STIs in young women. J Adolesc Health (2006) 1.84
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl (2005) 1.79
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol (2002) 1.73
Complications of right lobe living donor liver transplantation. J Hepatol (2009) 1.73
Pregnancy and birth history influence women's experience of menopause. Menopause (2008) 1.71
Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin Transplant (2007) 1.70
BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol (2013) 1.67
Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis (2004) 1.65
In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology (2006) 1.63
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. Obstet Gynecol (2005) 1.60
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg (2012) 1.59
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
Hypophosphatemia after 95 right-lobe living-donor hepatectomies for liver transplantation is not a significant source of morbidity. Transplantation (2003) 1.57
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation (2008) 1.52
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation (2009) 1.47
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer (2013) 1.47
Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol (2003) 1.47
Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci U S A (2006) 1.46
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood (2010) 1.45
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? Am J Obstet Gynecol (2008) 1.45
Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology (2011) 1.44
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology (2004) 1.39